Americans could soon pay significantly more for generic prescription drugs under the Trump administration's new tariff policy, according to the chief executive of one of India's largest pharmaceutical manufacturers.
Erez Israeli, CEO of Dr. Reddy's Laboratories, told CNBC's Inside India that President Donald Trump's proposed tariffs on imported generic medicines would inevitably translate into higher prices for patients in the United States because manufacturers operate on razor-thin profit margins.